CRYPTICS study met the primary efficacy endpoint measure, 24-hour chest tube drainage (Difference in LS Means was 142.0 mL; 95.576% confidence interval...
Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business...
POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mos...
Amneal Pharmaceuticals, Inc.announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a propos...
Global pharma major Lupin Limited (Lupin), announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisi...
New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...
Completion of submission batches and NDA-ready CMC package strengthens regulatory foundation for upcoming Phase 2b/3 trials and underscores Sen-Jam's lea...
ME Therapeutics Holdings Inc. a publicly listed biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased ...
US President Donald Trump has announced a 100% import tariff on all branded or patented pharmaceutical products, effective 1 October. The steep duty will d...
Avant Technologies Inc. announced a pivotal evolution in its business direction, emphasizing strategic partnerships through joint ventures and licensing ...
$25 million investment to meet growing global demand for medical devices and precision components. Expansion to quadruple manufacturing footprint for hi...
The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging...
Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new small molecule th...
Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and...
© 2025 Biopharma Boardroom. All Rights Reserved.
